Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040813 | 1.00 | IDO1 (0.38) | IDO1ANPEPCA1CA2KDM4E | |
| SCHEMBL151547 | 1.00 | IDO1 (0.38) | IDO1ANPEPCA1CA2KDM4E | |
| SCHEMBL1143179 | 0.77 | PARP1 (0.36) | IDO1ANPEPCA1CA2CYP2D6 | |
| SCHEMBL15233622 | 0.77 | PARP1 (0.36) | IDO1ANPEPCA1CA2CYP2D6 | |
| SCHEMBL23457245 | 0.71 | IDO1 (0.38) | IDO1CA1CA2KDM4EL3MBTL1 | |
| SCHEMBL6143052 | 0.71 | IDO1 (0.43) | IDO1ANPEPPLAU | |
| SCHEMBL17765425 | 0.71 | IDO1 (0.38) | IDO1CA1CA2KDM4EL3MBTL1 | |
| SCHEMBL1702930 | 0.71 | CYP19A1 (0.39) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL22554804 | 0.71 | CYP19A1 (0.39) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL2853835 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | claimed |
| CN-114380823-B | Imidazole-2-methylamine derivative and medical application thereof | 中国药科大学 | 2023-06-23 | — | — | CN | claimed |
| US-10968216-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-06 | — | — | US | claimed |
| EP-3621619-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | Arena Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | claimed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | claimed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | claimed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | claimed |
| WO-2018208848-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | claimed |
| WO-2018208847-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF PAIN FROM INFLAMMATORY BOWEL DISEASE | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-6528532-B1 | Benzenesulfonamide group | PHARMACOR INC. (CA) | 2003-03-04 | — | — | US | claimed |
| US-6498238-B1 | Glycopeptide antibacterial compounds, compositions containing same and methods of using same | PRINCETON UNIVERSITY | 2002-12-24 | — | — | US | claimed |
| WO-2002074719-A2 | INHIBITORS OF PLASMEPSINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2002-09-26 | — | — | WO | claimed |
| WO-2000069893-A1 | GLYCOPEPTIDE ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SAME AND METHODS OF USING SAME | MERCK & CO., INC. (US) | 2000-11-23 | — | — | WO | claimed |
| EP-0541168-B1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO INC (US) | 1998-03-11 | — | — | EP | claimed |
| US-5444062-A | Quinazolines derivatives for enhancing antitumor activity | PFIZER INC. (US) | 1995-08-22 | — | — | US | claimed |
| EP-0556310-B1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER (US) | 1995-07-05 | — | — | EP | claimed |
| EP-0556310-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY. | PFIZER (US) | 1993-08-25 | — | — | EP | claimed |
| WO-1992007844-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1992-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | IDO1 212/4885ANPEP 2194/4885CA1 114/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | IDO1 1290/4885ANPEP 4731/4885CA1 1259/4885 |
| US-10968216-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | IDO1 1283/4885ANPEP 4652/4885CA1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.